STRO-001
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Lymphoma
Conditions
B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Indolent Lymphoma, B Cells--Tumors
Trial Timeline
Feb 22, 2018 → Mar 15, 2024
NCT ID
NCT03424603About STRO-001
STRO-001 is a phase 1 stage product being developed by Sutro Biopharma for B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03424603. Target conditions include B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Lymphoma were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03424603 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Lymphoma